Bo Xu_CPDT 2018 - Engii
Biography
Dr. Bo Xu
Dr. Bo Xu
Roswell Park Comprehensive Cancer Institute and State University of New York at Buffalo, USA
Title: Updates on Guidelines and Biomarkers for Pathologic Diagnosis of Malignant Mesothelioma
Abstract: 
Malignant mesothelioma (MM) is a rare, aggressive cancer that affects the thin lining of body's internal organs, known as the mesothelium. There are about 3,000 new cases of MM each year in the U.S., according to a 2017 report from the Centers for Disease Control and Prevention. The pathologic diagnosis of malignant mesothelioma (MM) continues to evolve and be refined as more antibodies and molecular tests become available for general use. In this talk, the new guidelines for pathological diagnosis from 2017 International Mesothelioma Interest Group will be presented. In addition, the new emerging biomarkers that are used in immunohistochemical work-ups to aid pathological diagnosis of MM will be discussed.
Biography: 
Dr. Xu is an attending pathologist and Associate Professor of Oncology at Department of Pathology & Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and State University of New York at Buffalo School of Medicine. Dr. Xu received his MD from Nanjing Medical University, Faculty of Medicine in China and Ph.D. from Wright State University in USA. He obtained his post-doctoral fellowship training from Howard Hughes Medical Institute, Department of Microbiology & Immunology, Vanderbilt University School of Medicine; pathology residency from Department of Pathology, SUNY at Buffalo and Oncological Surgical Pathology Fellowship from Department of Pathology, Roswell Park Comprehensive Cancer Center. In addition, he had an intensive visiting fellowship at Section of Genitourinary Pathology, Indiana University School of Medicine. Dr. Xu is board certified for anatomic and clinical pathology by American Board of Pathology since 2010. His areas of expertise are Genitourologic and Thoracic Pathology. His special research interests are clinicopathologic correlation and translational research on urologic and male genital tumors, lung and mediastinal tumors. In collaboration with scientists and clinicians, Dr. Xu has published 45 research papers in peer reviewed journals, including high impact papers in "Science", "Molecular Cell Biology", "Journal of Biological Chemistry", "Journal of Immunology", "Modern Pathology". He has 29 abstracts accepted for presentation at national or international conferences. In addition, he served as reviewer and editorial board member for several journals. He was invited to give lectures at both national and international conferences. Currently, the H-index is 15 for his publications and his ResearchGate Score 34.08. He has been serving as President of Western New York Society of Pathologist since June, 2017.